Compile Data Set for Download or QSAR
Report error Found 65 Enz. Inhib. hit(s) with all data for entry = 1012
TargetComplement factor D(Human)
Achillion Pharmaceuticals

US Patent
LigandChemical structure of BindingDB Monomer ID 303051BDBM303051((2S,4R)-1-(2-(3- acetyl-5-(pyrimidin-5- ylamino)-1...)
Affinity DataIC50: 1.00E+3nMAssay Description:Human factor D (purified from human serum, Complement Technology, Inc.) at 80 nM final concentration is incubated with test compound at various conce...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/29/2019
Entry Details
US Patent

TargetComplement factor D(Human)
Achillion Pharmaceuticals

US Patent
LigandChemical structure of BindingDB Monomer ID 303052BDBM303052((2S,4R)-1-(2-(3- acetyl-5-(pyrimidin-5- ylamino)-...)
Affinity DataIC50: 1.00E+3nMAssay Description:Human factor D (purified from human serum, Complement Technology, Inc.) at 80 nM final concentration is incubated with test compound at various conce...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/29/2019
Entry Details
US Patent

TargetComplement factor D(Human)
Achillion Pharmaceuticals

US Patent
LigandChemical structure of BindingDB Monomer ID 303053BDBM303053((2S,4R)-1-(2-(3- acetyl-5-(pyrimidin-5- ylamino)-1...)
Affinity DataIC50: 1.00E+3nMAssay Description:Human factor D (purified from human serum, Complement Technology, Inc.) at 80 nM final concentration is incubated with test compound at various conce...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/29/2019
Entry Details
US Patent

TargetComplement factor D(Human)
Achillion Pharmaceuticals

US Patent
LigandChemical structure of BindingDB Monomer ID 303054BDBM303054((2S,4R)-1-(2-(3- acetyl-5-(pyrimidin-5- ylamino)-1...)
Affinity DataIC50: 1.00E+3nMAssay Description:Human factor D (purified from human serum, Complement Technology, Inc.) at 80 nM final concentration is incubated with test compound at various conce...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/29/2019
Entry Details
US Patent

TargetComplement factor D(Human)
Achillion Pharmaceuticals

US Patent
LigandChemical structure of BindingDB Monomer ID 303057BDBM303057((2S,4R)-1-(2-(3- acetyl-5-(pyrimidin-5- ylamino)...)
Affinity DataIC50: 1.00E+3nMAssay Description:Human factor D (purified from human serum, Complement Technology, Inc.) at 80 nM final concentration is incubated with test compound at various conce...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/29/2019
Entry Details
US Patent

TargetComplement factor D(Human)
Achillion Pharmaceuticals

US Patent
LigandChemical structure of BindingDB Monomer ID 303042BDBM303042((2S,4R)-1-(2-(3- acetyl-5-(pyrimidin-5- ylamino)-1...)
Affinity DataIC50: 1.00E+3nMAssay Description:Human factor D (purified from human serum, Complement Technology, Inc.) at 80 nM final concentration is incubated with test compound at various conce...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/29/2019
Entry Details
US Patent

TargetComplement factor D(Human)
Achillion Pharmaceuticals

US Patent
LigandChemical structure of BindingDB Monomer ID 303043BDBM303043((2S,4R)-1-(2-(3- acetyl-5-(pyrimidin-5- ylamino)-1...)
Affinity DataIC50: 1.00E+3nMAssay Description:Human factor D (purified from human serum, Complement Technology, Inc.) at 80 nM final concentration is incubated with test compound at various conce...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/29/2019
Entry Details
US Patent

TargetComplement factor D(Human)
Achillion Pharmaceuticals

US Patent
LigandChemical structure of BindingDB Monomer ID 302880BDBM302880((2S,4R)-1-(2-(3- acetyl-5-(pyrimidin-5- ylamino)-1...)
Affinity DataIC50: 1.00E+3nMAssay Description:Human factor D (purified from human serum, Complement Technology, Inc.) at 80 nM final concentration is incubated with test compound at various conce...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/29/2019
Entry Details
US Patent

TargetComplement factor D(Human)
Achillion Pharmaceuticals

US Patent
LigandChemical structure of BindingDB Monomer ID 302881BDBM302881((2S,4R)-1-(2-(3- acetyl-5-(pyrimidin-5- ylamino)-1...)
Affinity DataIC50: 1.00E+3nMAssay Description:Human factor D (purified from human serum, Complement Technology, Inc.) at 80 nM final concentration is incubated with test compound at various conce...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/29/2019
Entry Details
US Patent

TargetComplement factor D(Human)
Achillion Pharmaceuticals

US Patent
LigandChemical structure of BindingDB Monomer ID 302882BDBM302882(1-(2-((2S,4R)-2-(2'- chloro-2- fluorobiphenyl-3- y...)
Affinity DataIC50: 1.00E+3nMAssay Description:Human factor D (purified from human serum, Complement Technology, Inc.) at 80 nM final concentration is incubated with test compound at various conce...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/29/2019
Entry Details
US Patent

TargetComplement factor D(Human)
Achillion Pharmaceuticals

US Patent
LigandChemical structure of BindingDB Monomer ID 302883BDBM302883(1-(2-((2S,4R)-2-(2'- chloro-2- fluorobiphenyl-3- y...)
Affinity DataIC50: 1.00E+3nMAssay Description:Human factor D (purified from human serum, Complement Technology, Inc.) at 80 nM final concentration is incubated with test compound at various conce...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/29/2019
Entry Details
US Patent

TargetComplement factor D(Human)
Achillion Pharmaceuticals

US Patent
LigandChemical structure of BindingDB Monomer ID 302884BDBM302884(1-(2-((2S,4R)-2-(6- chloropyridin-2- ylcarbamoyl)-...)
Affinity DataIC50: 1.00E+3nMAssay Description:Human factor D (purified from human serum, Complement Technology, Inc.) at 80 nM final concentration is incubated with test compound at various conce...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/29/2019
Entry Details
US Patent

TargetComplement factor D(Human)
Achillion Pharmaceuticals

US Patent
LigandChemical structure of BindingDB Monomer ID 302889BDBM302889(1-(2-((2S,4R)-2-(6- chloropyridin-2- ylcarbamoyl)-...)
Affinity DataIC50: 1.00E+3nMAssay Description:Human factor D (purified from human serum, Complement Technology, Inc.) at 80 nM final concentration is incubated with test compound at various conce...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/29/2019
Entry Details
US Patent

TargetComplement factor D(Human)
Achillion Pharmaceuticals

US Patent
LigandChemical structure of BindingDB Monomer ID 302893BDBM302893(1-(2-((2S,4R)-2-(2'- chloro-2- fluorobiphenyl-3- y...)
Affinity DataIC50: 1.00E+3nMAssay Description:Human factor D (purified from human serum, Complement Technology, Inc.) at 80 nM final concentration is incubated with test compound at various conce...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/29/2019
Entry Details
US Patent

TargetComplement factor D(Human)
Achillion Pharmaceuticals

US Patent
LigandChemical structure of BindingDB Monomer ID 302900BDBM302900(1-(2-((2S,4R)-2-(2'- chloro-2- fluorobiphenyl-3- y...)
Affinity DataIC50: 1.00E+3nMAssay Description:Human factor D (purified from human serum, Complement Technology, Inc.) at 80 nM final concentration is incubated with test compound at various conce...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/29/2019
Entry Details
US Patent

TargetComplement factor D(Human)
Achillion Pharmaceuticals

US Patent
LigandChemical structure of BindingDB Monomer ID 303058BDBM303058((2S,4R)-1-(2-(3- acetyl-5-(pyrimidin-5- ylamino)-1...)
Affinity DataIC50: 1.00E+3nMAssay Description:Human factor D (purified from human serum, Complement Technology, Inc.) at 80 nM final concentration is incubated with test compound at various conce...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/29/2019
Entry Details
US Patent

TargetComplement factor D(Human)
Achillion Pharmaceuticals

US Patent
LigandChemical structure of BindingDB Monomer ID 303059BDBM303059((2S,4R)-1-(2-(3- acetyl-5-(pyrimidin-5- ylamino)-1...)
Affinity DataIC50: 1.00E+3nMAssay Description:Human factor D (purified from human serum, Complement Technology, Inc.) at 80 nM final concentration is incubated with test compound at various conce...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/29/2019
Entry Details
US Patent

TargetComplement factor D(Human)
Achillion Pharmaceuticals

US Patent
LigandChemical structure of BindingDB Monomer ID 303060BDBM303060((2S,4R)-1-(2-(3- acetyl-5-(pyrimidin-5- ylamino)-1...)
Affinity DataIC50: 1.00E+3nMAssay Description:Human factor D (purified from human serum, Complement Technology, Inc.) at 80 nM final concentration is incubated with test compound at various conce...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/29/2019
Entry Details
US Patent

TargetComplement factor D(Human)
Achillion Pharmaceuticals

US Patent
LigandChemical structure of BindingDB Monomer ID 302867BDBM302867((2S,4R)-1-(2-(3- acetyl-6- (trifluoromethylsulfon-...)
Affinity DataIC50: 1.00E+3nMAssay Description:Human factor D (purified from human serum, Complement Technology, Inc.) at 80 nM final concentration is incubated with test compound at various conce...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/29/2019
Entry Details
US Patent

TargetComplement factor D(Human)
Achillion Pharmaceuticals

US Patent
LigandChemical structure of BindingDB Monomer ID 302872BDBM302872((2S,4R)-1-(2-(3- acetyl-5-(pyrimidin-5- ylamino)-1...)
Affinity DataIC50: 1.00E+3nMAssay Description:Human factor D (purified from human serum, Complement Technology, Inc.) at 80 nM final concentration is incubated with test compound at various conce...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/29/2019
Entry Details
US Patent

TargetComplement factor D(Human)
Achillion Pharmaceuticals

US Patent
LigandChemical structure of BindingDB Monomer ID 302874BDBM302874((2S,4R)-1-(2-(3- acetyl-5-(pyrimidin-5- ylamino)-1...)
Affinity DataIC50: 1.00E+3nMAssay Description:Human factor D (purified from human serum, Complement Technology, Inc.) at 80 nM final concentration is incubated with test compound at various conce...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/29/2019
Entry Details
US Patent

TargetComplement factor D(Human)
Achillion Pharmaceuticals

US Patent
LigandChemical structure of BindingDB Monomer ID 302878BDBM302878((2S,4R)-1-(2-(3- acetyl-5-(5- fluoropyridin-3- yla...)
Affinity DataIC50: 1.00E+3nMAssay Description:Human factor D (purified from human serum, Complement Technology, Inc.) at 80 nM final concentration is incubated with test compound at various conce...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/29/2019
Entry Details
US Patent

TargetComplement factor D(Human)
Achillion Pharmaceuticals

US Patent
LigandChemical structure of BindingDB Monomer ID 302879BDBM302879((2S,4R)-1-(2-(3- acetyl-5-(pyrimidin-5- ylamino)-1...)
Affinity DataIC50: 1.00E+3nMAssay Description:Human factor D (purified from human serum, Complement Technology, Inc.) at 80 nM final concentration is incubated with test compound at various conce...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/29/2019
Entry Details
US Patent

TargetComplement factor D(Human)
Achillion Pharmaceuticals

US Patent
LigandChemical structure of BindingDB Monomer ID 303011BDBM303011((2S,4R)-1-(2-(3- acetyl-5-(pyrimidin-5- ylamino)-1...)
Affinity DataIC50: 1.00E+3nMAssay Description:Human factor D (purified from human serum, Complement Technology, Inc.) at 80 nM final concentration is incubated with test compound at various conce...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/29/2019
Entry Details
US Patent

TargetComplement factor D(Human)
Achillion Pharmaceuticals

US Patent
LigandChemical structure of BindingDB Monomer ID 303012BDBM303012((2S,4R)-1-(2-(3- acetyl-5-(pyrimidin-5- ylamino)-1...)
Affinity DataIC50: 1.00E+3nMAssay Description:Human factor D (purified from human serum, Complement Technology, Inc.) at 80 nM final concentration is incubated with test compound at various conce...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/29/2019
Entry Details
US Patent

TargetComplement factor D(Human)
Achillion Pharmaceuticals

US Patent
LigandChemical structure of BindingDB Monomer ID 303013BDBM303013((2S,4R)-1-(2-(3- acetyl-5-(pyrimidin-5- ylamino)-1...)
Affinity DataIC50: 1.00E+3nMAssay Description:Human factor D (purified from human serum, Complement Technology, Inc.) at 80 nM final concentration is incubated with test compound at various conce...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/29/2019
Entry Details
US Patent

TargetComplement factor D(Human)
Achillion Pharmaceuticals

US Patent
LigandChemical structure of BindingDB Monomer ID 303015BDBM303015((2S,4R)-1-(2-(3- acetyl-5-(pyrimidin-5- ylamino)-1...)
Affinity DataIC50: 1.00E+3nMAssay Description:Human factor D (purified from human serum, Complement Technology, Inc.) at 80 nM final concentration is incubated with test compound at various conce...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/29/2019
Entry Details
US Patent

TargetComplement factor D(Human)
Achillion Pharmaceuticals

US Patent
LigandChemical structure of BindingDB Monomer ID 303024BDBM303024((2S,4R)-1-(2-(3- acetyl-5-(pyrimidin-5- ylamino)-1...)
Affinity DataIC50: 1.00E+3nMAssay Description:Human factor D (purified from human serum, Complement Technology, Inc.) at 80 nM final concentration is incubated with test compound at various conce...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/29/2019
Entry Details
US Patent

TargetComplement factor D(Human)
Achillion Pharmaceuticals

US Patent
LigandChemical structure of BindingDB Monomer ID 302928BDBM302928((2S,4R)-1-(2-(3- acetyl-5-(pyrimidin-5- ylamino)-1...)
Affinity DataIC50: 1.00E+3nMAssay Description:Human factor D (purified from human serum, Complement Technology, Inc.) at 80 nM final concentration is incubated with test compound at various conce...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/29/2019
Entry Details
US Patent

TargetComplement factor D(Human)
Achillion Pharmaceuticals

US Patent
LigandChemical structure of BindingDB Monomer ID 302930BDBM302930((2S,4R)-1-(2-(3- acetyl-5-(pyrimidin-5- ylamino)-1...)
Affinity DataIC50: 1.00E+3nMAssay Description:Human factor D (purified from human serum, Complement Technology, Inc.) at 80 nM final concentration is incubated with test compound at various conce...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/29/2019
Entry Details
US Patent

TargetComplement factor D(Human)
Achillion Pharmaceuticals

US Patent
LigandChemical structure of BindingDB Monomer ID 302931BDBM302931((2S,4R)-1-(2-(3- acetyl-5-(pyrimidin-5- ylamino)-1...)
Affinity DataIC50: 1.00E+3nMAssay Description:Human factor D (purified from human serum, Complement Technology, Inc.) at 80 nM final concentration is incubated with test compound at various conce...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/29/2019
Entry Details
US Patent

TargetComplement factor D(Human)
Achillion Pharmaceuticals

US Patent
LigandChemical structure of BindingDB Monomer ID 303009BDBM303009((2S,4R)-1-(2-(3- acetyl-5-(pyrimidin-5- ylamino)-1...)
Affinity DataIC50: 1.00E+3nMAssay Description:Human factor D (purified from human serum, Complement Technology, Inc.) at 80 nM final concentration is incubated with test compound at various conce...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/29/2019
Entry Details
US Patent

TargetComplement factor D(Human)
Achillion Pharmaceuticals

US Patent
LigandChemical structure of BindingDB Monomer ID 303010BDBM303010((2S,4R)-1-(2-(3- acetyl-5-(pyrimidin-5- ylamino)-1...)
Affinity DataIC50: 1.00E+3nMAssay Description:Human factor D (purified from human serum, Complement Technology, Inc.) at 80 nM final concentration is incubated with test compound at various conce...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/29/2019
Entry Details
US Patent

TargetComplement factor D(Human)
Achillion Pharmaceuticals

US Patent
LigandChemical structure of BindingDB Monomer ID 303037BDBM303037((2S,4R)-1-(2-(3- acetyl-5-(pyrimidin-5- ylamino)-1...)
Affinity DataIC50: 1.00E+3nMAssay Description:Human factor D (purified from human serum, Complement Technology, Inc.) at 80 nM final concentration is incubated with test compound at various conce...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/29/2019
Entry Details
US Patent

TargetComplement factor D(Human)
Achillion Pharmaceuticals

US Patent
LigandChemical structure of BindingDB Monomer ID 303038BDBM303038((2S,4R)-1-(2-(3- acetyl-5-(pyrimidin-5- ylamino)-1...)
Affinity DataIC50: 1.00E+3nMAssay Description:Human factor D (purified from human serum, Complement Technology, Inc.) at 80 nM final concentration is incubated with test compound at various conce...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/29/2019
Entry Details
US Patent

TargetComplement factor D(Human)
Achillion Pharmaceuticals

US Patent
LigandChemical structure of BindingDB Monomer ID 303039BDBM303039((2S,4R)-1-(2-(3- acetyl-5-(pyrimidin-5- ylamino)-1...)
Affinity DataIC50: 1.00E+3nMAssay Description:Human factor D (purified from human serum, Complement Technology, Inc.) at 80 nM final concentration is incubated with test compound at various conce...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/29/2019
Entry Details
US Patent

TargetComplement factor D(Human)
Achillion Pharmaceuticals

US Patent
LigandChemical structure of BindingDB Monomer ID 303040BDBM303040((2S,4R)-1-(2-(3- acetyl-5-(pyrimidin-5- ylamino)-1...)
Affinity DataIC50: 1.00E+3nMAssay Description:Human factor D (purified from human serum, Complement Technology, Inc.) at 80 nM final concentration is incubated with test compound at various conce...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/29/2019
Entry Details
US Patent

TargetComplement factor D(Human)
Achillion Pharmaceuticals

US Patent
LigandChemical structure of BindingDB Monomer ID 303041BDBM303041((2S,4R)-1-(2-(3- acetyl-5-(pyrimidin-5- ylamino)-1...)
Affinity DataIC50: 1.00E+3nMAssay Description:Human factor D (purified from human serum, Complement Technology, Inc.) at 80 nM final concentration is incubated with test compound at various conce...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/29/2019
Entry Details
US Patent

TargetComplement factor D(Human)
Achillion Pharmaceuticals

US Patent
LigandChemical structure of BindingDB Monomer ID 303026BDBM303026((2S,4R)-1-(2-(3- acetyl-5-(pyrimidin-5- ylamino)-1...)
Affinity DataIC50: 1.00E+3nMAssay Description:Human factor D (purified from human serum, Complement Technology, Inc.) at 80 nM final concentration is incubated with test compound at various conce...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/29/2019
Entry Details
US Patent

TargetComplement factor D(Human)
Achillion Pharmaceuticals

US Patent
LigandChemical structure of BindingDB Monomer ID 303028BDBM303028((2S,4R)-1-(2-(3- acetyl-5-(pyrimidin-5- ylamino)-1...)
Affinity DataIC50: 1.00E+3nMAssay Description:Human factor D (purified from human serum, Complement Technology, Inc.) at 80 nM final concentration is incubated with test compound at various conce...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/29/2019
Entry Details
US Patent

TargetComplement factor D(Human)
Achillion Pharmaceuticals

US Patent
LigandChemical structure of BindingDB Monomer ID 303030BDBM303030((2S,4R)-1-(2-(3- acetyl-5-(pyrimidin-5- ylamino)-1...)
Affinity DataIC50: 1.00E+3nMAssay Description:Human factor D (purified from human serum, Complement Technology, Inc.) at 80 nM final concentration is incubated with test compound at various conce...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/29/2019
Entry Details
US Patent

TargetComplement factor D(Human)
Achillion Pharmaceuticals

US Patent
LigandChemical structure of BindingDB Monomer ID 303033BDBM303033((2S,4R)-1-(2-(3- acetyl-5-(pyrimidin-5- ylamino)-1...)
Affinity DataIC50: 1.00E+3nMAssay Description:Human factor D (purified from human serum, Complement Technology, Inc.) at 80 nM final concentration is incubated with test compound at various conce...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/29/2019
Entry Details
US Patent

TargetComplement factor D(Human)
Achillion Pharmaceuticals

US Patent
LigandChemical structure of BindingDB Monomer ID 303050BDBM303050((2S,4R)-1-(2-(3- acetyl-5-(pyrimidin-5- ylamino)-1...)
Affinity DataIC50: 5.50E+3nMAssay Description:Human factor D (purified from human serum, Complement Technology, Inc.) at 80 nM final concentration is incubated with test compound at various conce...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/29/2019
Entry Details
US Patent

TargetComplement factor D(Human)
Achillion Pharmaceuticals

US Patent
LigandChemical structure of BindingDB Monomer ID 303016BDBM303016((2S,4R)-1-(2-(3- acetyl-5-(pyrimidin-5- ylamino)-1...)
Affinity DataIC50: 5.50E+3nMAssay Description:Human factor D (purified from human serum, Complement Technology, Inc.) at 80 nM final concentration is incubated with test compound at various conce...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/29/2019
Entry Details
US Patent

TargetComplement factor D(Human)
Achillion Pharmaceuticals

US Patent
LigandChemical structure of BindingDB Monomer ID 303025BDBM303025((2S,4R)-1-(2-(3- acetyl-5-(pyrimidin-5- ylamino)-1...)
Affinity DataIC50: 5.50E+3nMAssay Description:Human factor D (purified from human serum, Complement Technology, Inc.) at 80 nM final concentration is incubated with test compound at various conce...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/29/2019
Entry Details
US Patent

TargetComplement factor D(Human)
Achillion Pharmaceuticals

US Patent
LigandChemical structure of BindingDB Monomer ID 302902BDBM302902(((3-acetyl-1-(2- ((2S,4R)-2-(2'-chloro- 2-fluorobi...)
Affinity DataIC50: 5.50E+3nMAssay Description:Human factor D (purified from human serum, Complement Technology, Inc.) at 80 nM final concentration is incubated with test compound at various conce...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/29/2019
Entry Details
US Patent

TargetComplement factor D(Human)
Achillion Pharmaceuticals

US Patent
LigandChemical structure of BindingDB Monomer ID 302903BDBM302903((2S,4R)-1-(2-(3- acetyl-5-(pyrimidin-5- ylamino)-1...)
Affinity DataIC50: 5.50E+3nMAssay Description:Human factor D (purified from human serum, Complement Technology, Inc.) at 80 nM final concentration is incubated with test compound at various conce...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/29/2019
Entry Details
US Patent

TargetComplement factor D(Human)
Achillion Pharmaceuticals

US Patent
LigandChemical structure of BindingDB Monomer ID 303044BDBM303044((2S,4R)-1-(2-(3- acetyl-5-(pyrimidin-5- ylamino)-1...)
Affinity DataIC50: 5.50E+3nMAssay Description:Human factor D (purified from human serum, Complement Technology, Inc.) at 80 nM final concentration is incubated with test compound at various conce...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/29/2019
Entry Details
US Patent

TargetComplement factor D(Human)
Achillion Pharmaceuticals

US Patent
LigandChemical structure of BindingDB Monomer ID 303046BDBM303046((2S,4R)-1-(2-(3- acetyl-5-(pyrimidin-5- ylamino)-1...)
Affinity DataIC50: 5.50E+3nMAssay Description:Human factor D (purified from human serum, Complement Technology, Inc.) at 80 nM final concentration is incubated with test compound at various conce...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/29/2019
Entry Details
US Patent

TargetComplement factor D(Human)
Achillion Pharmaceuticals

US Patent
LigandChemical structure of BindingDB Monomer ID 303047BDBM303047((2S,4R)-1-(2-(3- acetyl-5-(pyrimidin-5- ylamino)-1...)
Affinity DataIC50: 5.50E+3nMAssay Description:Human factor D (purified from human serum, Complement Technology, Inc.) at 80 nM final concentration is incubated with test compound at various conce...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/29/2019
Entry Details
US Patent

Displayed 1 to 50 (of 65 total ) | Next | Last >>
Jump to: